Division of Pediatric Endocrinology, Hacettepe University Medical School, Ankara, Turkey.
Clin Endocrinol (Oxf). 2012 Jan;76(1):126-30. doi: 10.1111/j.1365-2265.2011.04185.x.
Intravenous GnRH stimulation test has often been used as gold standard test for the evaluation of hypothalamic-pituitary-gonadal axis in the diagnosis of central precocious puberty (CPP) and in the assessment of pubertal suppression. However, this test is time-consuming, costly and uncomfortable for the patients. We aimed to analyse the validity of single LH sample 90 min after GnRH analogue (GnRHa) administration in the evaluation of gonadotrophin suppression during CPP therapy and to determine a cut-off level for LH indicating adequate suppression.
Prospective study.
One hundred and forty-two patients with CPP were included in this study. Peak LH level during iv GnRH stimulation test after the third dose of GnRHa was compared with LH level 90 min after injection of the 3rd dose of GnRHa.
There was a positive correlation between LH level following a GnRHa injection and peak LH during standard iv GnRH stimulation test (r = 0·83; P < 0·0001). A LH value of 2·5 mIU/ml or less 90 min after GnRHa injection was considered to be the cut-off for the determination of pubertal suppression (sensitivity and specificity was 100% and 88%, respectively). In 117 patients, gonadotrophin suppression was existed according to both GnRHa and iv GnRH tests. In 25 patients, gonadotrophin suppression was not found in the GnRHa test. However, 16 of them were suppressed according to the iv GnRH test.
Single LH determination 90 min after GnRHa administration using a cut-off level of 2·5 mIU/ml reflects pubertal suppression with a high sensitivity and specificity. However, this test may fail to show pubertal suppression in some cases. Those patients who appear to be inadequately suppressed should be reassessed using standard iv GnRH stimulation test for optimal dose adjustment.
静脉内 GnRH 刺激试验常被用作评价下丘脑-垂体-性腺轴在中枢性性早熟(CPP)诊断和青春期抑制评估中的金标准试验。然而,该试验耗时、昂贵且患者不适。我们旨在分析 GnRH 类似物(GnRHa)给药后 90 分钟单次 LH 样本在 CPP 治疗中评价促性腺激素抑制的有效性,并确定指示充分抑制的 LH 截止值。
前瞻性研究。
本研究纳入了 142 例 CPP 患者。将 GnRH 刺激试验后第三次 GnRHa 静脉注射时的 LH 峰值与第三次 GnRHa 注射后 90 分钟的 LH 水平进行比较。
GnRHa 注射后 LH 水平与标准静脉内 GnRH 刺激试验时的 LH 峰值呈正相关(r=0.83;P<0.0001)。GnRHa 注射后 90 分钟 LH 值为 2.5 mIU/ml 或更低被认为是确定青春期抑制的截止值(灵敏度和特异性分别为 100%和 88%)。在 117 例患者中,根据 GnRHa 和 iv GnRH 试验均存在促性腺激素抑制。在 25 例患者中,GnRHa 试验未发现促性腺激素抑制,但其中 16 例根据 iv GnRH 试验被抑制。
GnRHa 给药后 90 分钟使用 2.5 mIU/ml 的截止值进行单次 LH 测定反映了青春期抑制,具有较高的灵敏度和特异性。然而,在某些情况下,该试验可能无法显示青春期抑制。那些似乎抑制不足的患者应使用标准的 iv GnRH 刺激试验重新评估,以进行最佳剂量调整。